Objective-This study determined the role of angiotensin-converting enzyme (ACE) on the development of angiotensin I-induced atherosclerosis and the contribution of leukocyte-specific expression of this enzyme. Approach and Results-To define the contribution of ACE-dependent activity to angiotensin II synthesis in atherosclerotic development, male low-density lipoprotein receptor −/− mice were fed a fat-enriched diet and infused with either angiotensin I or angiotensin II. The same infusion rate of these peptides had equivalent effects on atherosclerotic development. Coinfusion of an ACE inhibitor, enalapril, ablated angiotensin I-augmented atherosclerosis but had no effect on angiotensin II-induced lesion development. ACE protein was detected in several cell types in atherosclerotic lesions, with a predominance in macrophages. This cell type secreted angiotensin II, which was ablated by ACE inhibition. To study whether leukocyte ACE contributed to atherosclerosis, irradiated male low-density lipoprotein receptor −/− mice were repopulated with bone marrow-derived cells from either ACE +/+ or ACE −/− mice and fed the fat-enriched diet for 12 weeks. Chimeric mice with ACE deficiency in bone marrow-derived cells had modestly reduced atherosclerotic lesions in aortic arches but had no effects in aortic roots.
R ecent studies have demonstrated an evolving complexity of the renin-angiotensin system with a diversity of bioactive peptides that are derived from a multitude of enzymes. 1 Angiotensin-converting enzyme (ACE) is considered the major enzyme responsible for converting the inactive decapeptide, angiotensin I (AngI), to the bioactive octapeptide, angiotensin II (AngII). AngII is a major bioactive component of the renin-angiotensin system and has been demonstrated as a crucial mediator for atherosclerotic lesion development. 2 Direct evidence that AngII promotes atherosclerosis has been gained through chronic subcutaneous infusion of AngII into either apolipoprotein E −/− or low-density lipoprotein (LDL) receptor −/− mice. [3] [4] [5] Conversely, pharmacological inhibition of AngII actions through angiotensin type 1 (AT1) receptor blockade profoundly decreases experimental atherosclerosis. [6] [7] [8] [9] Furthermore, genetic depletion of AT1a receptors markedly reduces hypercholesterolemia or AngII infusion-induced atherosclerosis. 6, 10 It is clear that AngII, either produced endogenously or administered exogenously, is a robust stimulus for atherosclerotic lesion formation. However, it is unclear whether the AngII precursor, AngI, augments lesion formation through an ACE-dependent mechanism.
The activity of ACE is considered the major systemic mechanism of converting AngI to AngII. However, several other enzymes also have dipeptidyl carboxylpeptidase activity within local tissue environments to convert AngI into AngII. [11] [12] [13] These include chymase and cathepsin G. In addition, the activity of ACE is not exclusive to AngI conversion because it also cleaves many other peptides, including bradykinin, substance P, and N-acetyl-seryl-aspartyl-lysyl-proline. Given the promiscuity of substrates for ACE, the use of ACE inhibitors to inhibit the renin-angiotensin system pharmacologically in hypercholesterolemia-induced atherosclerosis does not indicate a definitive role for AngI to AngII conversion as the primary mechanism regulating lesion formation.
ACE expression is most abundant in endothelial cells. However, it is also expressed in several different cell types of atherosclerotic lesions, such as smooth muscle cells and macrophages, in both animal and human atherosclerotic lesions. 10, 14, 15 Macrophages have the potential to be a local source for AngII, given the predominance of this cell type in lesions and the ability to synthesize this octapeptide through a renin-dependent mechanism. 16 However, the role of ACE in macrophage AngII production and lesion formation has not been defined.
To define the role of ACE-mediated AngII production in experimental atherosclerosis, we initially determined effects of inhibition of this enzyme on lesion formation during infusion of AngI, the direct AngII precursor. ACE protein within atherosclerotic lesions was present in several cell types. Because some of the ACE within atherosclerotic lesions colocalized with CD68-immunostained cells, we explored the role of the enzyme in this cell type in vitro for AngII production and abundance of chemokines that modulate atherosclerosis. To determine the contribution of leukocyte expression of ACE to the development of atherosclerosis, we transplanted ACE +/+ or ACE −/− bone marrow-derived cells into irradiated LDL receptor −/− mice. Although whole-body ACE inhibition profoundly reduced atherosclerosis in both the aortic root and arch regions, depletion of leukocyte ACE only modestly reduced atherosclerotic lesion in aortic arches, but had no effect in aortic roots.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

ACE-Dependent Effects on Atherosclerosis Were Attributed to Conversion of AngI to AngII
Many studies have demonstrated that chronic AngII infusion augments atherosclerosis. 3, 4 To determine whether ACE contributes to atherosclerosis in an AngII-dependent mechanism, male LDL receptor −/− mice were infused with AngI (the direct precursor of AngII) alone or coinfused with an ACE inhibitor, enalapril, for 4 weeks. The purpose of using exogenous infusion of AngI versus AngII was to dissect the effect clearly of ACE in the AngI-AngII axis on the development of atherosclerosis. Chronic infusion of AngI in the absence or presence of enalapril did not affect body weight and plasma cholesterol concentrations ( Table II in the online-only Data Supplement) in LDL receptor −/− mice. AngI infusion led to pronounced increases in systolic blood pressure that were ablated by coinfusion of enalapril ( Table II in ACE acts on multiple substrates, and a previous study reported that ACE inhibition reduced atherosclerosis through an AngII-independent mechanism. 17 Therefore, we determined whether ACE inhibition also reduced atherosclerosis in AngIIinfused mice. Male LDL receptor −/− mice were infused with AngI, AngII, or coinfused with both AngII and enalapril for 4 weeks. Mice from the 3 groups had comparable body weight, systolic blood pressure, plasma cholesterol concentration ( Table III in the online-only Data Supplement), and lipoprotein cholesterol distribution (data not shown). AngI infusion had an equivalent effect as AngII infusion on percent lesion area in the aortic arch. However, in contrast to ACE inhibition in AngI-infused mice, ACE inhibition did not alter AngIIinduced augmentation of atherosclerotic lesions ( Figure 1B ).
Macrophages Secreted AngII Through an ACE-Dependent Mechanism
We have detected all classical components in the generation of AngII in mouse atherosclerotic lesions, which were primarily associated with macrophages. 10 Among the reninangiotensin system components, ACE immunoreactivity was ubiquitous in all cell types within atherosclerotic lesions and medial layers of the aorta (Figure 2 and Figure II in the online-only Data Supplement). Because ACE was abundant in macrophages of atherosclerotic lesions, and this cell type is predominant in atherosclerotic lesions, we determined whether cultured macrophages secreted AngII into culture media via an ACE-dependent mechanism. As determined by a high-performance liquid chromatographic resolution of angiotensin peptides followed by radioimmunoassay, AngII was secreted from cultured mouse macrophages. The secretion of AngII was abolished in cells incubated with an ACE inhibitor, captopril ( Figure 3A ).
AngII stimulates synthesis of an inflammatory chemokine, monocyte chemoattractant protein-1 (MCP-1), which plays a crucial role in the development of atherosclerosis by recruiting monocytes probably through interaction with C-C chemokine receptor type 2. 18, 19 To determine whether ACE 
ACE Deficiency in Bone Marrow-Derived Cells Modestly Reduced Atherosclerosis
Irradiated male LDL receptor −/− mice were repopulated with bone marrow-derived cells from either ACE +/+ or ACE −/− mice. Successful repopulation of donor cells was confirmed by ACE genotyping of genomic DNA from bone marrow-derived cells of recipient mice after termination ( Figure 4A ) and mRNA analyses of peritoneal macrophages from these recipient mice ( Figure IV in the online-only Data Supplement).
Recipient mice repopulated with ACE +/+ versus ACE -/bone marrow-derived cells had no significant difference in body weight, systolic blood pressure, serum ACE activity, plasma renin concentrations, plasma cholesterol concentrations (Table) , and plasma lipoprotein cholesterol distributions ( Figure V in the online-only Data Supplement). ACE -/mice are anemic as a result of a combination of increased plasma N-acetyl-seryl-aspartyl-lysyl-proline and absence of plasma AngII. 20 However, we did not find any abnormality of red blood cell number, hemoglobin, or hematocrit in mice repopulated with ACE -/bone marrow-derived cells (Table) . In addition, leukocyte (total and subpopulations) and platelet numbers were not different between the 2 chimeric groups.
Atherosclerotic lesions were quantified on the intimal surface of aortic arches and throughout the aortic root (representative images shown in Figures VI and VII in the online-only Data Supplement). ACE deficiency in bone marrow-derived cells led to a significant reduction of percent lesion area in aortic arches ( Figure 4B ) but no significant changes of mean lesion area in aortic roots ( Figure 4C and Figure VIII in the online-only Data Supplement).
Discussion
In the present study, we provide direct evidence that ACEdependent conversion of AngI into AngII plays an important role in atherosclerosis, as demonstrated by direct infusion of exogenous AngI versus AngII with or without enalapril, an ACE inhibitor. ACE protein was present in many cell types of atherosclerotic lesions, including macrophages, the predominant infiltrating cell type in experimental atherosclerotic lesions. Production of AngII in macrophages, a main leukocyte type, was abolished with ACE inhibition. Abundance of an inflammatory chemokine, MCP-1, implicated in lesion formation was also reduced in ACE-deficient macrophages. A major novel finding of this study is that ACE deficiency in bone marrow-derived cells reduced hypercholesterolemiainduced atherosclerosis, although this effect was modest and only in the aortic arch region. ACE was initially characterized as an enzyme for conversion of the inactive decapetide AngI to the biologically active octapeptide, AngII. Many studies have demonstrated that chronic AngII infusion accelerates atherosclerosis. [3] [4] [5] There is also compelling evidence that ACE inhibition reduces atherosclerosis. 21 In addition to ACE, there are several other enzymes that are capable of converting AngI to AngII. The most substantial evidence has accumulated from a serine protease, chymase, which has been considered to play a critical role in tissue generation of AngII from AngI. 11, 22 Chymase was associated with increased AngII and atherosclerosis in aortas of monkeys fed a high-cholesterol diet. 23 Furthermore, increased AngII generation through a chymase-dependent mechanism in human atherosclerotic aorta is associated with progression of atherosclerosis. 22 However, there is no direct evidence that chymase inhibition reduces atherosclerosis through an AngII-based mechanism. In the present study, no difference was found on lesion size augmented by AngI between mice infused with either vehicle or enalapril. These results demonstrate that ACE, rather than chymase, contributes to atherosclerosis through enzymatic conversion activity to generate AngII from the cleavage of AngI.
Using an infusion approach to deliver AngI versus AngII enabled us to address the role clearly of ACE in the conversion of AngI to AngII on the development of atherosclerosis. The specificity of AngI to AngII conversion through ACE as the mechanism for acceleration of atherosclerosis is evident from lack of effect of ACE inhibition to influence atherosclerosis induced by infusing AngII directly. These findings support that antiatherosclerotic effects of ACE inhibition are attributed to direct inhibition of AngII generation. In contrast to the present study, a previous study reported that enalapril reduced atherosclerosis in carotid arteries of apolipoprotein E −/− mice through AngII-independent mechanisms. 17 In addition to differences of mouse strain and location of atherosclerosis quantified between the 2 studies, a major difference is dose of enalapril. We have titrated doses of enalapril to inhibit ACE previously. 24 We have also demonstrated that subcutaneous infusion of enalapril at a rate of 4 mg/kg per day ablated conversion of AngI to AngII. However, this dose is much lower compared with the dose (25 mg/kg per day) used in the previous study. 17 It is possible that this high dose of enalapril extended to effects beyond inhibiting AngI conversion to AngII.
As the most abundant infiltrating cell type accumulating in atherosclerotic lesions, macrophages play a crucial role in the development of atherosclerosis. 25 Although angiotensinogen, renin, and angiotensin peptides are present predominantly in macrophages of atherosclerotic lesions, 10 ACE is ubiquitous in many cell types of the aortic wall. 10 ACE is also present in macrophages of human atherosclerotic lesions, although the abundance relative to other cell types varies during lesion development. 14, 15 The present study provides evidence that one major leukocyte type, macrophages, secretes AngII via an ACE-dependent mechanism. AngII induces a variety of inflammatory factors, including MCP-1, that have a major role in initiating atherosclerosis by recruiting macrophages and monocytes to the vessel wall. [26] [27] [28] Abundance of MCP-1 mRNA and secreted protein was diminished in macrophages from ACE-deficient mice. These results are consistent with an atherogenic role of ACE through promoting leukocyte infiltration into atherosclerotic lesions.
Table. Comparison of Recipient Mice Repopulated With Bone Marrow-Derived Cells From ACE +/+ vs ACE −/− Mice
Although there are many studies demonstrating a role of pharmacological inhibition of ACE in experimental atherosclerosis, studies using ACE-deficient mice are sparse and have yielded conflicting results in atherosclerosis. One study reported that heterozygous deficiency of ACE did not change atherosclerosis in apolipoprotein E +/− mice. 29 Another mouse model that has been studied is ACE.2 model, which lacks membrane-bound ACE but contains a truncated form of ACE in the circulating blood. 30 Both heterozygous and homozygous ACE.2 mice (apolipoprotein E −/− background) had reduced atherosclerosis. 31, 32 To our knowledge, the present study is the first to define the role of leukocyte ACE in atherosclerosis. Bone marrow transplantation approach has been used extensively to determine effects of many genes of interest in leukocytes on the development of atherosclerosis in mouse models. 16, [33] [34] [35] [36] The successful repopulation of bone marrow-derived cells from ACE +/+ versus ACE −/− mice was confirmed by ACE genotyping of bone marrow-derived cells and presence versus absence of ACE mRNA in peritoneal macrophages in recipient LDL receptor -/mice. Leukocyte ACE deficiency in chimeric LDL receptor -/mice led to a reduction of percent atherosclerotic lesion area in the aortic arch region as measured by an en face method. The magnitude of lesion size reduction is comparable with what was observed previously in ACE.2 mice. 32 However, ACE deficiency in bone marrow-derived cells did not reduce lesion area in aortic roots of chimeric mice as measured using serial cross sections. One potential interpretation of these differences is the diverse origins of the resident cell types in different regions of the aortic wall during embryonic development that may influence leukocyte infiltration. 37 In addition, ACE is ubiquitously present in resident cell types of the aortic wall, such as endothelial cells, smooth muscle cells, and fibroblasts, [38] [39] [40] [41] inferring that ACE from these resident cell types has potentials to contribute to the development of atherosclerosis. As demonstrated in our previous studies and the present study, leukocyte renin 16 and ACE contribute to atherosclerosis, whereas AT1a receptor in a single cell type (leukocytes, endothelial cells, or smooth muscle cells) 16, 36, 42 is not sufficient to promote atherosclerosis. Lack of effect of AT1a receptor deletion in a single cell type may be as a result of the need for AT1a receptor stimulation exerting a coordinated response among several cell types. We will explore this assumption in a future study.
In summary, this study demonstrated that ACE inhibition reduced AngI but not AngII-induced atherosclerosis. Although systemic ACE inhibition markedly reduces atherosclerotic lesion formation in mice in the 2 vascular beds studied, leukocyte-specific ACE only modestly reduced atherosclerosis in the aortic arch but had no significant effect in the aortic root. In addition to leukocytes, ACE is present in many other cell types of atherosclerotic lesions, including endothelial and smooth muscle cells. Future studies are needed to determine the relative contributions of ACE in these cell types to atherosclerotic lesion formation.
Despite the convincing evidence that pharmacological inhibition of whole-body angiotensin-converting enzyme (ACE) reduces atherosclerosis in animal models, the mechanistic basis for this beneficial effect has not been elucidated. In addition, it has been well recognized that ACE has effects independent of converting angiotensin I into angiotensin II. This article provides insights into 2 aspects. First, our in vivo studies provide direct evidence that ACE is the enzyme responsible for conversion of angiotensin I into angiotensin II that contributes to the consequent induction of atherosclerosis. Second, deficiency of ACE in leukocytes modestly reduces hypercholesterolemia-induced atherosclerosis in the aortic arch region but not in the aortic root. Because ACE is present in resident vascular cell types in both experimental and human atherosclerotic lesions, subsequent studies will determine whether deficiency of ACE in resident cell types influences atherosclerosis and the potential cross-talk between and among different cell types.
Significance
